27472389|t|Dimerization of EGFR and HER2 induces breast cancer cell motility through STAT1 -dependent ACTA2 induction
27472389|a|The dimerization of EGFR and HER2 is associated with poor prognosis such as induction of tumor growth and cell invasion compared to when EGFR remains as a homodimer. However, the mechanism for events after dimerization in breast cancer models is not clear. We found that expressions of alpha-smooth muscle actin (ACTA2) and signal transducer and activator of transcription 1 (STAT1) significantly increased with transient or stable overexpression of HER2 in EGFR - positive breast cancer cells. ACTA2 and STAT1 expression was also increased in HER2 - positive breast cancer patients. In contrast, ACTA2 expression was decreased by HER2 siRNA. Next, we investigated the co-relation between STAT1 and ACTA2 expression. Basal ACTA2 expression was significantly decreased by treatment with the STAT1 inhibitor fludarabine or the JAK2 inhibitor AG490. In contrast, ACTA2 expression was increased by STAT1 overexpression. Levels of ACTA2, STAT1, and HER2 were increased and relapse free survival was decreased in high-risk breast cancer patients. We also investigated the effect of ACTA2 on cell motility, which was suppressed by ACTA2 shRNA overexpression in MDA-MB231 HER2 and 4T1 mammary carcinoma cells. The number of lung metastatic nodules was significantly decreased in ACTA2 knockdown mice. Taken together, these results demonstrated that induction of ACTA2 by EGFR and HER2 dimerization was regulated through a JAK2 / STAT1 signaling pathway, and aberrant ACTA2 expression accelerated the invasiveness and metastasis of breast cancer cells.
27472389	0	12	Dimerization	T067	C2350408
27472389	16	20	EGFR	T116,T126,T192	C0034802
27472389	25	29	HER2	T116,T126,T192	C0069515
27472389	38	51	breast cancer	T191	C0006142
27472389	52	65	cell motility	T040	C0007608
27472389	74	79	STAT1	T116,T123	C0287920
27472389	91	96	ACTA2	T116,T123	C2716282
27472389	97	106	induction	T169	C0205263
27472389	111	123	dimerization	T067	C2350408
27472389	127	131	EGFR	T116,T126,T192	C0034802
27472389	136	140	HER2	T116,T126,T192	C0069515
27472389	165	174	prognosis	T058	C0033325
27472389	183	192	induction	T169	C0205263
27472389	196	208	tumor growth	T191	C0598934
27472389	213	226	cell invasion	T046	C2699153
27472389	227	235	compared	T052	C1707455
27472389	244	248	EGFR	T116,T126,T192	C0034802
27472389	262	271	homodimer	T104	C0596448
27472389	286	295	mechanism	T169	C0441712
27472389	313	325	dimerization	T067	C2350408
27472389	329	342	breast cancer	T191	C0006142
27472389	343	349	models	T075	C0026336
27472389	378	389	expressions	T045	C1171362
27472389	393	418	alpha-smooth muscle actin	T116,T123	C2716282
27472389	420	425	ACTA2	T116,T123	C2716282
27472389	431	481	signal transducer and activator of transcription 1	T116,T123	C0287920
27472389	483	488	STAT1	T116,T123	C0287920
27472389	504	513	increased	T081	C0205217
27472389	539	553	overexpression	T045	C1514559
27472389	557	561	HER2	T116,T126,T192	C0069515
27472389	565	569	EGFR	T116,T126,T192	C0034802
27472389	572	580	positive	T033	C1446409
27472389	581	594	breast cancer	T191	C0006142
27472389	595	600	cells	T025	C0007634
27472389	602	607	ACTA2	T116,T123	C2716282
27472389	612	617	STAT1	T116,T123	C0287920
27472389	618	628	expression	T045	C1171362
27472389	638	647	increased	T081	C0205217
27472389	651	655	HER2	T116,T126,T192	C0069515
27472389	658	666	positive	T033	C1446409
27472389	667	680	breast cancer	T191	C0006142
27472389	681	689	patients	T101	C0030705
27472389	704	709	ACTA2	T116,T123	C2716282
27472389	710	720	expression	T045	C1171362
27472389	725	734	decreased	T081	C0205216
27472389	738	748	HER2 siRNA	T114,T123	C1099354
27472389	796	801	STAT1	T116,T123	C0287920
27472389	806	811	ACTA2	T116,T123	C2716282
27472389	812	822	expression	T045	C1171362
27472389	830	835	ACTA2	T116,T123	C2716282
27472389	836	846	expression	T045	C1171362
27472389	865	874	decreased	T081	C0205216
27472389	878	887	treatment	T061	C0087111
27472389	897	912	STAT1 inhibitor	T121	C1254351
27472389	913	924	fludarabine	T114,T121	C0059985
27472389	932	946	JAK2 inhibitor	T121	C1254351
27472389	947	952	AG490	T109,T121	C0381241
27472389	967	972	ACTA2	T116,T123	C2716282
27472389	973	983	expression	T045	C1171362
27472389	988	997	increased	T081	C0205217
27472389	1001	1006	STAT1	T116,T123	C0287920
27472389	1007	1021	overexpression	T045	C1514559
27472389	1033	1038	ACTA2	T116,T123	C2716282
27472389	1040	1045	STAT1	T116,T123	C0287920
27472389	1051	1055	HER2	T116,T126,T192	C0069515
27472389	1061	1070	increased	T081	C0205217
27472389	1083	1096	free survival	T081	C0242793
27472389	1101	1110	decreased	T081	C0205216
27472389	1114	1123	high-risk	T033	C0332167
27472389	1124	1137	breast cancer	T191	C0006142
27472389	1138	1146	patients	T101	C0030705
27472389	1156	1168	investigated	T169	C1292732
27472389	1183	1188	ACTA2	T116,T123	C2716282
27472389	1192	1205	cell motility	T040	C0007608
27472389	1217	1227	suppressed	T169	C1260953
27472389	1231	1242	ACTA2 shRNA	T114	C2930586
27472389	1243	1257	overexpression	T045	C1514559
27472389	1261	1270	MDA-MB231	T025	C1512505
27472389	1271	1275	HER2	T116,T126,T192	C0069515
27472389	1280	1307	4T1 mammary carcinoma cells	T025	C1512505
27472389	1323	1346	lung metastatic nodules	T033	C0034079
27472389	1365	1374	decreased	T081	C0205216
27472389	1378	1383	ACTA2	T116,T123	C2716282
27472389	1384	1398	knockdown mice	T015	C0206745
27472389	1448	1457	induction	T169	C0205263
27472389	1461	1466	ACTA2	T116,T123	C2716282
27472389	1470	1474	EGFR	T116,T126,T192	C0034802
27472389	1479	1483	HER2	T116,T126,T192	C0069515
27472389	1484	1496	dimerization	T067	C2350408
27472389	1521	1525	JAK2	T116,T126	C0169661
27472389	1528	1533	STAT1	T116,T123	C0287920
27472389	1534	1551	signaling pathway	T044	C0037080
27472389	1566	1571	ACTA2	T116,T123	C2716282
27472389	1572	1582	expression	T045	C1171362
27472389	1572	1582	expression	T045	C1171362
27472389	1599	1611	invasiveness	T046	C0027626
27472389	1616	1626	metastasis	T191	C0027627
27472389	1630	1643	breast cancer	T191	C0006142
27472389	1644	1649	cells	T025	C0007634